Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst [Seeking Alpha]
Immuneering Corporation - Class A (IMRX)
Company Research
Source: Seeking Alpha
IMRX's atebimetinib plus mGnP achieved superior 9-month overall survival (86%) and progression-free survival (53%) compared to standard of care. Key catalysts include expected FDA feedback in Q4 2025, potential phase 3 initiation by end of 2025, and expansion into other solid tumors and NSCLC. Recent collaborations with Eli Lilly and Regeneron, plus upcoming financings, position IMRX for further pipeline advancement despite financial and clinical risks. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » Thicha Satapitanon/iStock via Getty Images The last time I wrote about Immuneering Corporation ( NASDAQ: IMRX ) it was in a Seeking Alpha article entitled "Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone." With respect to this article, I talked about positive More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical s
Show less
Read more
Impact Snapshot
Event Time:
IMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRX alerts
High impacting Immuneering Corporation - Class A news events
Weekly update
A roundup of the hottest topics
IMRX
News
- Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Immuneering to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Immuneering (NASDAQ:IMRX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMRX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</aMarketBeat
- Immuneering (NASDAQ:IMRX) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.MarketBeat
- Immuneering Corporation (IMRX) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
IMRX
Earnings
- 11/12/25 - Miss
IMRX
Sec Filings
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- 10/21/25 - Form SCHEDULE
- IMRX's page on the SEC website